Galectin Therapeutics Inc. (GALT) NASDAQ
2.43
-0.1811(-6.94%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.43
-0.1811(-6.94%)
Currency In USD
| Previous Close | 2.61 |
| Open | 2.6 |
| Day High | 2.63 |
| Day Low | 2.42 |
| 52-Week High | 7.13 |
| 52-Week Low | 1.27 |
| Volume | 210,215.43 |
| Average Volume | 367,787 |
| Market Cap | 159.96M |
| PE | -5.92 |
| EPS | -0.41 |
| Moving Average 50 Days | 2.43 |
| Moving Average 200 Days | 3.84 |
| Change | -0.18 |
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
GlobeNewswire Inc.
Feb 26, 2026 9:05 PM GMT
NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtu
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
GlobeNewswire Inc.
Dec 19, 2025 1:00 PM GMT
NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that the U.S. Food and Dr
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting
GlobeNewswire Inc.
Nov 10, 2025 1:00 PM GMT
New biomarker analyses from the NAVIGATE trial demonstrated consistent antifibrotic effects of belapectin 2 mg/kgUsing established criteria for clinically meaningful worsening, a lower proportion of patients treated with belapectin 2 mg/kg experience